Biortus, a wholly owned subsidiary of Pharmaron, is a protein-focused CRO serving global drug discovery community in protein production, assay and screening, and structural biology including protein NMR, X-ray crystallography, and cryo-EM. Since 2009, Biortus's fully integrated pipeline has contributed to SBDD programs to large body of clients including top 20 pharmaceutical and bio-pharma multi-national corporations (MNCs). Biortus's top notch protein production team has delivered more than 4000 target proteins and protein complexes including degradation complexes, GPCR, transporters, ion channels, and many others. Biortus owns several unique compound libraries and has delivered many novel hits to clients for FBDD and non-classical modalities including covalent targeting cystine and lysine residues. Biortus's NMR structural biology capability is well poised to drive hit finding and hit confirmation for discovery programs targeting intrinsically disordered proteins (IDPs). Biortus' crystallography platform has delivered over tens of thousands of co-xtal structures to support clients' SBDD programs. Biortus owns one of the top cryo-EM service platforms in the industry, with a line of state-of-the-art microscopes and computation clusters, a team of cryo-EM specialists, and more importantly, rich experiences in the application of SPA, MicroED, and cryo-ET, to variety of drug targets and novel modalities.  

To help clients expedite discovery process, Biortus launched non-competing internal lead generation campaign and the goal is to build lead generation packages (LGSuite) for a series of drug targets. Each LGSuite contains essential drug discovery tools and materials including ready-to-use proteins, crystal and/or cryo-EM structures, and assays and hits. So far Biortus has assemble a protein catalog with over 3,000 novel targets, a structural database of more than 1,000 protein structures, and a compound library with over 10,000 novel ligands. The company is committed to providing strong support for pioneering innovation through "novel targets, novel mechanisms, and novel molecules." Within Pharmaron family, Biortus joins force with other teams to accelerate and empower the advancement of global biopharmaceuticals.